Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System

被引:143
作者
Heneweer, Carola [2 ,3 ]
Holland, Jason P. [1 ]
Divilov, Vadim [1 ]
Carlin, Sean [4 ]
Lewis, Jason S. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, Radiochem Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10065 USA
[3] Univ Hosp Schleswig Holstein, Dept Diagnost Radiol, Kiel, Germany
[4] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA
关键词
enhanced permeability and retention (EPR) effect; prostate cancer; albumin; positron emission tomography; Zr-89; contrast-enhanced ultrasound; IN-VIVO; MACROMOLECULAR THERAPEUTICS; CANCER-CHEMOTHERAPY; SOLID TUMOR; ALBUMIN; MECHANISM; SMANCS; PROGRESSION; EXPRESSION; ADVANTAGES;
D O I
10.2967/jnumed.110.083998
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Targeted nanoparticle-based technologies show increasing prevalence in radiotracer design. As a consequence, quantitative contribution of nonspecific accumulation in the target tissue, mainly governed by the enhanced permeability and retention (EPR) effect, becomes highly relevant for evaluating the specificity of these new agents. This study investigated the influence of different tumor phenotypes on the EPR effect, hypothesizing that a baseline level of uptake must be exceeded to visualize high and specific uptake of a targeted macromolecular radiotracer. Methods: These preliminary studies use Zr-89-labeled mouse serum albumin (Zr-89-desfer-rioxamine-mAlb) as a model radiotracer to assess uptake and retention in 3 xenograft models of human prostate cancer (CWR22rv1, DU-145, and PC-3). Experiments include PET and contrast-enhanced ultrasound imaging to assess morphology, vascularization, and radiotracer uptake; temporal ex vivo biodistribution studies to quantify radiotracer uptake over time; and histologic and autoradiographic studies to evaluate the intra-and intertumoral distribution of Zr-89-desfer-rioxamine-mAlb. Results: Early uptake profiles show statistically significant but overall small differences in radiotracer uptake between different tumor phenotypes. By 20 h, nonspecific radiotracer uptake was found to be independent of tumor size and phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models. Conclusion: These studies suggest that minimal differences in tumor uptake exist at early time points, dependent on the tumor type. However, these differences equalize over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection. These data provide strong support for the introduction of mandatory experimental controls of future macromolecular or nanoparticle-based drugs, particularly regarding the development of targeted radiotracers.
引用
收藏
页码:625 / 633
页数:9
相关论文
共 29 条
  • [11] Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
    Holland, Jason P.
    Caldas-Lopes, Eloisi
    Divilov, Vadim
    Longo, Valerie A.
    Taldone, Tony
    Zatorska, Danuta
    Chiosis, Gabriela
    Lewis, Jason S.
    [J]. PLOS ONE, 2010, 5 (01):
  • [12] Standardized methods for the production of high specific-activity zirconium-89
    Holland, Jason P.
    Sheh, Yiauchung
    Lewis, Jason S.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (07) : 729 - 739
  • [13] Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces
    Kim, JH
    Bronson, CL
    Hayton, WL
    Radmacher, MD
    Roopenian, DC
    Robinson, JM
    Anderson, CL
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2006, 290 (02): : G352 - G360
  • [14] PERMEABILITY OF RHEUMATOID AND NORMAL HUMAN SYNOVIUM TO SPECIFIC PLASMA-PROTEINS
    LEVICK, JR
    [J]. ARTHRITIS AND RHEUMATISM, 1981, 24 (12): : 1550 - 1560
  • [15] Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS
    Maeda, H
    Sawa, T
    Konno, T
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) : 47 - 61
  • [16] SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy (Reprinted from Advanced Drug Delivery Reviews, vol 6, pg 181-202, 1991)
    Maeda, H
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) : 169 - 185
  • [17] CONJUGATES OF ANTICANCER AGENTS AND POLYMERS - ADVANTAGES OF MACROMOLECULAR THERAPEUTICS INVIVO
    MAEDA, H
    SEYMOUR, LW
    MIYAMOTO, Y
    [J]. BIOCONJUGATE CHEMISTRY, 1992, 3 (05) : 351 - 362
  • [18] Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
    Maeda, Hiroshi
    [J]. BIOCONJUGATE CHEMISTRY, 2010, 21 (05) : 797 - 802
  • [19] MATSUMURA Y, 1986, CANCER RES, V46, P6387
  • [20] Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies
    Mimeault, M
    Batra, SK
    [J]. CARCINOGENESIS, 2006, 27 (01) : 1 - 22